X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3647) 3647
science & technology (3186) 3186
life sciences & biomedicine (3120) 3120
imatinib mesylate (2173) 2173
male (2163) 2163
female (1930) 1930
benzamides (1867) 1867
middle aged (1558) 1558
adult (1422) 1422
pyrimidines - therapeutic use (1340) 1340
piperazines - therapeutic use (1293) 1293
pyrimidines - adverse effects (1221) 1221
piperazines - adverse effects (1158) 1158
benzamides - therapeutic use (1131) 1131
aged (1122) 1122
oncology (1098) 1098
benzamides - adverse effects (956) 956
antineoplastic agents - therapeutic use (954) 954
animals (935) 935
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (914) 914
antineoplastic agents - adverse effects (872) 872
treatment outcome (822) 822
benzamides - pharmacology (782) 782
hematology (741) 741
pharmacology & pharmacy (644) 644
imatinib (626) 626
pyrimidines - administration & dosage (624) 624
benzamides - administration & dosage (585) 585
piperazines - administration & dosage (584) 584
protein kinase inhibitors - therapeutic use (457) 457
adolescent (429) 429
chronic myeloid leukemia (414) 414
abridged index medicus (408) 408
dose-response relationship, drug (389) 389
protein-tyrosine kinases - antagonists & inhibitors (387) 387
antineoplastic agents - administration & dosage (386) 386
drug therapy (367) 367
care and treatment (364) 364
protein kinase inhibitors - adverse effects (358) 358
aged, 80 and over (352) 352
mice (349) 349
medicine & public health (345) 345
cancer (338) 338
research (337) 337
young adult (324) 324
piperazines - pharmacology (308) 308
gastrointestinal stromal tumors - drug therapy (305) 305
pyrimidines - pharmacology (298) 298
antineoplastic agents (276) 276
double-blind method (272) 272
time factors (260) 260
analysis (257) 257
rats (256) 256
drug resistance, neoplasm (251) 251
benzamides - pharmacokinetics (250) 250
antimitotic agents (249) 249
clinical trials as topic (248) 248
dasatinib (239) 239
leukemia (238) 238
moclobemide (238) 238
neurosciences & neurology (236) 236
general & internal medicine (231) 231
follow-up studies (224) 224
drug administration schedule (207) 207
administration, oral (204) 204
antineoplastic agents - pharmacology (204) 204
disease-free survival (203) 203
antineoplastic combined chemotherapy protocols - therapeutic use (202) 202
leukemia, myelogenous, chronic, bcr-abl positive - genetics (202) 202
medicine, general & internal (199) 199
neurosciences (197) 197
clinical trials (195) 195
leukemia, myelogenous, chronic, bcr-abl positive - pathology (187) 187
hematology, oncology and palliative medicine (186) 186
health aspects (184) 184
protein kinase inhibitors - administration & dosage (182) 182
thiazoles - therapeutic use (182) 182
prognosis (180) 180
risk factors (180) 180
mutation (177) 177
disease models, animal (171) 171
tumors (168) 168
fusion proteins, bcr-abl - genetics (164) 164
hemic and lymphatic diseases (161) 161
remission induction (161) 161
psychiatry (159) 159
chemotherapy (156) 156
internal medicine (156) 156
drug interactions (154) 154
tyrosine (153) 153
leukemia, myeloid, chronic-phase - drug therapy (151) 151
child (146) 146
dosage and administration (145) 145
gastrointestinal stromal tumors - pathology (145) 145
protein kinase inhibitors - pharmacology (140) 140
disease progression (138) 138
aminopyridines - therapeutic use (135) 135
pharmacology/toxicology (135) 135
retrospective studies (134) 134
depressive disorder - drug therapy (132) 132
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3916) 3916
French (99) 99
Japanese (94) 94
German (46) 46
Spanish (46) 46
Chinese (27) 27
Russian (24) 24
Italian (14) 14
Hungarian (4) 4
Swedish (4) 4
Danish (3) 3
Dutch (3) 3
Polish (3) 3
Czech (2) 2
Hebrew (2) 2
Portuguese (2) 2
Croatian (1) 1
Korean (1) 1
Norwegian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Academy of Dermatology, ISSN 0190-9622, 2008, Volume 58, Issue 4, pp. 545 - 570
Journal Article
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
British journal of haematology, ISSN 0007-1048, 01/2015, Volume 168, Issue 1, pp. 69 - 81
Summary Bosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and... 
BCR‐ABL1 | CML | tyrosine kinase inhibitor | bosutinib | chronic myeloid leukaemia | Chronic myeloid leukaemia | Tyrosine kinase inhibitor | Bosutinib | BCR-ABL1 | Life Sciences & Biomedicine | Hematology | Science & Technology | Piperazines - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Nitriles - administration & dosage | Benzamides - administration & dosage | Benzamides - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Odds Ratio | Benzamides - adverse effects | Aniline Compounds - administration & dosage | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Leukemia, Myeloid, Chronic-Phase - diagnosis | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Quinolines - therapeutic use | Aniline Compounds - therapeutic use | Mutation | Aniline Compounds - adverse effects | Nitriles - adverse effects | Quinolines - adverse effects | Nitriles - therapeutic use | Index Medicus | Haematological Malignancy
Journal Article
Journal Article
Journal Article